Tesofensine
Metabolic (non-peptide) · By Preptide Pro editorial team · Last updated
Tesofensine is a metabolic (non-peptide) peptide, and it is not FDA-approved. A small-molecule monoamine reuptake inhibitor, not a peptide. It has been studied in clinical trials for obesity.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 11370864 |
|---|---|
| CAS number | 195875-84-4 |
| Molecular formula | C17H23Cl2NO |
| Molecular weight | 328.3 g/mol |
| Other names | Tesofensine, NS-2330, tesofensina, NS2330, NS 2330, TESOFENSINUM, RefChem:188318, Tesofensine [INN] |
Is Tesofensine FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on Tesofensine?
PubMed lists 56 records for “tesofensine”, of which 11 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Investigations Into the Metabolism and Elimination of Tesofensine in Human Urine. | Drug Test Anal | 2026 Sep |
| Structural basis for pharmacotherapeutic action of triple reuptake inhibitors. | Nat Commun | 2025 Dec 14 |
| Sex-specific effects of appetite suppressants on stereotypy in rats. | PLoS One | 2025 |
| Tesofensine, a novel antiobesity drug, silences GABAergic hypothalamic neurons. | PLoS One | 2024 |
| Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity. | Eur J Endocrinol | 2022 May 9 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.